

meningococcal disease caused by groups A, C, W-135 and Y *Neisseria meningitidis*. Group B capsular PS is similar to the PS structure expressed in certain human tissues, thus making it a poor immunogen. Furthermore, if used as a vaccine, the possibility exists of it inducing an autoimmune response. Thus, a need remains to develop additional meningococcal vaccines, particularly for group B and group X meningococcal serogroups.

This application claims immunogenic conjugates including at least one polysaccharide conjugated to a group B factor H binding protein (fHbp). Also claimed are immunogenic conjugates including at least one polysaccharide conjugated to a Neisserial surface protein A (NspA). Additionally, improved methods for preparing conjugates are claimed.

Potential Commercial Applications:

- Multivalent meningitis vaccine
- Research tool

Competitive Advantages:

- Higher vaccine yield
- More efficient conjugation method
- Lower cost vaccines

Development Stage:

- Pre-clinical
- In vitro data available
- In vivo data available (animal)

Inventors: Che-Hung Robert Lee (FDA/CBER), Vavlerian Pinto (EM), Elizabeth Moran (EM), Robert Burden (EM)

Intellectual Property: HHS Reference No. E-082-2012/0—U.S. Application No. 61/651,382 filed 24 May 2012.

Related Technologies:

- HHS Reference No. E-301-2003/0—U.S. Application No. 13/243,480 filed 06 Aug 2004, claiming priority to 06 Aug 2003
- HHS Reference No. E-085-2005/0—U.S. Patent 8,173,135 issued 08 May 2012; U.S. Application No. 13/440,856 filed 05 Apr 2012, claiming priority to 17 Mar 2006

Licensing Contact: Peter A. Soukas; 301-435-4646; ps193c@nih.gov

Collaborative Research Opportunity: The FDA/CBER is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize Multivalent Meningococcal Conjugates and Methods for Preparing Conjugates. For collaboration opportunities, please contact Che-Hung Robert Lee at robert.lee@fda.hhs.gov or 301-451-5934.

Enhanced Cancer Therapy Using Photoimmunotherapy (PIT) in Combination With Anti-Cancer Agents

Description of Technology: The invention is in the field of

Photoimmunotherapy (PIT). More specifically, the invention relates to antibody-fluorophore conjugates where the antibody is specific for cancer cells and the fluorophore is IR700 dye. Binding of such conjugates to targeted cancer cells followed by irradiation with near infrared light (NIR) was shown to kill cancer cells in a highly specific manner. Furthermore, the invention discloses that the therapeutic effect of the PIT conjugate is significantly enhanced by the administration of one or more anti-cancer agents following the irradiation step. This is achieved by the markedly rapid accumulation of the therapeutic agent in the PIT-treated tissue. Also provided in the invention are wearable devices that incorporate NIR light emitting diodes (LEDs) and can be used to activate the PIT conjugates.

Potential Commercial Applications: Anti-cancer therapy.

Competitive Advantages:

- Highly specific to cancer cells
- Do not affect surrounding normal cells
- Negligible toxicity
- Enhancement of therapeutic effects when administered in combination with one or more other therapeutic agents
- Possible to follow the cell killing process in real time, using fluorescence lifetime imaging

Development Stage: In vivo data available (animal).

Inventors: Hisataka Kobayashi and Peter L. Choyke (NCI).

Publications:

1. Mitsunaga M, et al. Immediate in vivo target-specific cancer cell death after near infrared photoimmunotherapy. *BMC Cancer* 2012 Aug 8;12: 345. [PMID 22873679]
2. Mitsunaga M, et al. Near-infrared theranostic photoimmunotherapy (PIT): Repeated exposure of light enhances the effect of immunoconjugate. *Bioconjug Chem.* 2012 Mar 21;23(3):604-9. [PMID 22369484]
3. Mitsunaga M, et al. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. *Nat Med.* 2011 Nov6;17(12):1685-91. [PMID 22057348]

Intellectual Property:

- HHS Reference No. E-205-2010/2—PCT Application No. PCT/US2012/044421 filed 27 Jun 2012
- HHS Reference No. E-250-2010/1—U.S. Application No. 13/180,111 filed 11 Jul 2011
- HHS Reference No. E-205-2010/0—U.S. Provisional Application No. 61/636,079 filed 09 Jul 2010

Licensing Contact: Uri Reichman, Ph.D., MBA; 301-435-4616; reichmau@mail.nih.gov.

Dated: January 18, 2013.

Richard U. Rodriguez,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2013-01620 Filed 1-25-13; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel; Time-Sensitive Obesity Applications.

Date: February 15, 2013.

Time: 10:00 p.m. to 11:30 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Michele L. Barnard, Ph.D., Scientific Review Officer, Review Branch, DEA, NIDDK, National Institutes of Health, Room 753, 6707 Democracy Boulevard, Bethesda, MD 20892-2542, (301) 594-8898, barnardm@extra.niddd.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS)

Dated: January 18, 2013.

David Clary,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013-01621 Filed 1-25-13; 8:45 am]

BILLING CODE 4140-01-P